This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutTALZENNA MoATalzenna MoAgBRCA testingIdentifying patientsGuidelinesStudy designStudy designBaseline characteristicsEfficacy & SafetyTALZENNA efficacyPrimary endpoint & subgroup analysisSecondary endpoints: ORRSecondary endpoint: OSExploratory endpoints: DoR & TTRTALZENNA safetySafety and tolerabillityAdverse eventsHaematologic/Nonhaematologic AEsPatient-reported outcomes with TALZENNAPatient-reported outcomesGHS/QoLBreast symptomsDosingDosingDose recommendation and special populationsDose modifications/managementPatient ProfilesSupport & ResourcesSupport & ResourcesMaterialsVideosElevateElevatePersonalising Breast Cancer TreatmentUnderstanding and Optimising PARP Inhibitors for mBCPARP Inhibitors in mBC: the role of Real World Evidence
Selected baseline characteristics1,2​​​​​​​
Scroll left to view table

TALZENNA (n=287) Chemotherapy* (n=144)
Demographics
Age, median (range), y 45 (27.0-84.0) 50 (24.0-88.0)
<50 y, No. (%) 182 (63.4) 67 (46.5)
50 y to <65 y, No. (%) 78 (27.2) 67 (46.5)
≥65 y, No. (%) 27 (9.4) 10 (6.9)
Female, No. (%) 283 (98.6) 141 (97.9)
Clinical status
Stage of BC

Locally advanced, No. (%) 15 (5.2) 9 (6.2)
Metastatic, No. (%) 271 (94.4) 135 (93.8)
ECOG PS 0/1/2, (%) 53.3/44.3/2.1 58.3/39.6/1.4
Measurable disease by investigator, No. (%) 219 (76.3) 114 (79.2)
History of CNS metastases, No. (%) 43 (15.0) 20 (13.9)
Visceral disease, No. (%) 200 (69.7) 103 (71.5)
Disease-free interval (initial diagnosis to ABC) <12 months, No. (%) 108 (37.6) 42 (29.2)
Hormone receptor status, No. (%)
TNBC 130 (45.3) 60 (41.7)
HR+/HER2- 157 (54.7) 84 (58.3)
BRCA status by central or local laboratory assessment, No. (%)
BRCA1-mutation positive 133 (46.3) 63 (43.8)
BRCA2-mutation positive 154 (53.7) 81 (56.3)
Prior cytotoxic regimens for ABC, No. (%)
0 111 (38.7) 54 (37.5)
1 107 (37.3) 54 (37.5)
2 57 (19.9) 28 (19.4)
3 11 (3.8) 8 (5.6)
≥4 1 (0.3) 0 (0.0)
Number of patients who received following prior therapies, No. (%)
Taxane 262 (91.3) 130 (90.3)
Anthracycline 243 (84.7) 115 (79.9)
Platinum 46 (16.0) 30 (20.8)
Adapted from TALZENNA SmPC, and Litton et al. N Engl J Med. 2018.2
ABC=advanced breast cancer; BC=breast cancer; BRCA=breast cancer susceptibility gene; CNS=central nervous system; ECOG PS=Eastern Cooperative Oncology Group performance status; gBRCA=germline breast cancer susceptibility gene; GHS=global health status; HER2-=human epidermal growth factor receptor 2 negative; HR+=hormone receptor-positive; PFS=progression-free survival; QoL=quality of life; TNBC=triple-negative breast cancer.Capecitabine, eribulin, gemcitabine, or vinorelbine. Patients had a deleterious or suspected deleterious gBRCA mutation detected using a clinical trial assay.1Percentages do not add up to 100 due to rounding. Explore more Efficacy & safety
References:TALZENNA Summary of Product Characteristics. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753-763. Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526-1535.
​​​​​​​ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of full SmPC for how to report adverse reactions.

Legal Category: S1A 
Further information is available upon request

PP-TAL-IRL-0059 April 2023
About Significantly longer PFS 

Superior to chemotherapy in delaying disease progression

See the data 
Improved patient-reported outcomes

Significant improvements in GHS/QoL and breast symptoms3​​​​​​​

See the results
TALZENNA Summary of Product Characteristics Product CharacteristicsLoading

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024